Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
WHO approves Regeneron drug ["]cocktail["] for treatment
The WHO announced Friday it was recommending a cocktail of monoclonal antibodies manufactured by the US biotech firm Regeneron and marketed by Swiss pharmaceutical giant Roche to treat COVID-19 in certain patients. ... The cocktail, marketed as REGEN-COV in the US and Ronapreve elsewhere, was recommended only for certain patients, namely those who had a previous illness or are at risk of falling seriously ill from COVID-19 and facing time in intensive care.
US President Donald Trump when he had COVID-19.
for a weekend in October 2020
The WHO was joined by Doctors Without Borders in expressing concerns about the high cost of the treatment. ["]Global public health["] will depend on pharmaceutical manufacturers and governments working together to bring costs down, especially in the developing world, the UN health agency said, adding other agencies were involved in talks with Roche.

Doctors Without Borders said Regeneron has filed patent applications in at least 11 impoverished nations. Japan was first to authorize its use last July. The European Union, US, India, Switzerland and Canada have already approved the drug combination for emergency use.

archived Fri Aug 6th, 2021, Sat Oct 31st, 2020, Wed Oct 7th, 2020, Tue Aug 13th, 2019
by Cat on Fri Sep 24th, 2021 at 07:40:49 PM EST
[ Parent ]

Others have rated this comment as follows:


Occasional Series